DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Author: Vanessa Ngan, Staff Writer, 2003.
Pemphigoid gestationis is a rare pregnancy-associated autoimmune skin disease that is characterised by an itchy rash that develops into blisters. It is most common during the second and third trimesters of pregnancy. It was previously known as herpes gestationis although it has no association with the herpes virus whatsoever.
Pemphigoid gestationis is an autoimmune blistering disease, which basically means that an individual's immune system starts reacting against his or her own tissue. Immunoglobulin type G (IgG) autoantibodies (known as the PG factor) cause the damage.
In pemphigoid gestationis, the target is a protein known as BPAG2 (also called BP180), found within the basement membrane, which is the zone between the epidermis and the dermis (the top and middle layers of skin). BPAG2 is within the hemidesmosome, the cell component that sticks the epidermal keratinocyte cells to the dermis.
The antibody attack results in inflammation and separation of the epidermis from the dermis allowing fluid to build up and create a blister.
Most patients present with an intensely itchy hive-like rash during mid to late pregnancy (13 to 40 weeks gestation).
In some cases, pemphigoid gestationis occurs throughout pregnancy. Symptoms may lessen or spontaneously resolve towards the end of the pregnancy but this is short-lived, as 75-80% of women will experience a flare-up around delivery. In most cases, symptoms resolve days later after giving birth, however, in some, the disease remains active for months or years. Commencement of menstrual periods, use of oral contraceptives or further pregnancies may cause flare-ups.
Diagnosis generally requires a skin biopsy, which shows typical features of subepidermal blistering, similar in microscopic appearance to bullous pemphigoid (BP) or epidermolysis bullosa acquisita (EBA). Pemphigoid gestationis is confirmed by direct immunofluorescence staining of the biopsy to reveal antibodies. It can be distinguished from BP and EBA using salt-split samples of skin. In some cases, circulating antibodies can be detected by a blood test (indirect immunofluorescence test).
The primary aim of treatment is to relieve itching, prevent blister formation and treat secondary infections. Topical corticosteroids are used in mild disease whilst oral corticosteroids are necessary in more extensive cases. Minimum effective doses should be used to reduce the risk of side effects to both mother and fetus.
In most cases, pemphigoid gestationis resolves spontaneously within days after delivery so treatment can be tapered off and stopped. Complications are rare but may include:
See the DermNet NZ bookstore.
© 2019 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.